Gonadorelin
Hormonal · By Preptide Pro editorial team · Last updated
Gonadorelin is a hormonal peptide, and it has an FDA-approved product. A synthetic form of gonadotropin-releasing hormone (GnRH). It was previously FDA-approved as a diagnostic product and is still used in veterinary medicine.
Previously FDA-approved (discontinued)Chemistry (PubChem)
| PubChem CID | 638793 |
|---|---|
| CAS number | 33515-09-2 |
| Molecular formula | C55H75N17O13 |
| Molecular weight | 1182.3 g/mol |
| Other names | GONADORELIN, Gonadorelina, GnRH-I, Gonadorelinum, Fertagyl, LH-Releasing factor, Luforan, Lutrefact |
Is Gonadorelin FDA-approved?
| Brand | Application | Status | Sponsor |
|---|---|---|---|
| FACTREL | NDA018123 | Discontinued | HIKMA |
| LUTREPULSE KIT | NDA019687 | Discontinued | FERRING |
How much research is there on Gonadorelin?
PubMed lists 43,360 records for “gonadorelin”, of which 3,521 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Deoxynivalenol exposure promotes apoptosis and disrupts GnRH-dependent LH production in pituitary gonadotrope-like cells. | Mol Cell Endocrinol | 2027 Jan |
| Stigmasterol alleviates central precocious puberty by targeting the IGF-1/PI3K/Akt/mTOR signaling pathway and modulating the Kisspeptin/GnRH axis. | Biochim Biophys Acta Mol Basis Dis | 2027 Jan |
| Restoring ovulation in functional hypothalamic amenorrhea: impact of polycystic ovarian morphology on hormonal response to pulsatile GnRH. | Gynecol Endocrinol | 2026 Dec 31 |
| Relugolix combination therapy in symptomatic adenomyosis and uterine fibroids: a case series. | Gynecol Endocrinol | 2026 Dec 31 |
| Protocol flexibility in PCOS: a combination of controlled ovarian stimulation and endometrial preparation strategies shows no impact on live birth outcomes after frozen embryo transfer-a retrospective cohort study. | Gynecol Endocrinol | 2026 Dec 31 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.